Metoclopramide Hydrochloride (Metoclopramide)

Trade Name : Metoclopramide

Pharmaceutical Associates, Inc.

SOLUTION

Strength 5 mg/5mL

METOCLOPRAMIDE HYDROCHLORIDE Dopamine D2 Antagonists [MoA],Dopamine-2 Receptor Antagonist [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Metoclopramide Hydrochloride (Metoclopramide) which is also known as Metoclopramide and Manufactured by Pharmaceutical Associates, Inc.. It is available in strength of 5 mg/5mL per ml. Read more

Metoclopramide Hydrochloride (Metoclopramide) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • WARNING: TARDIVE DYSKINESIA
  • See full prescribing information for complete boxed warning
  • Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage (n n n )n n n
  • Discontinue metoclopramide in patients who develop signs or symptoms of TD (n n n )n n n
  • Avoid treatment with metoclopramide for longer than 12 weeks because of the risk of developing TD with longer-term use (n n n , n n n , n n n , n n n )n n n
  • No data
  • Metoclopramide is indicated for the:
  • Limitations of Use
  • Metoclopramide is not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates n n n n
  • Metoclopramide is indicated for the:
  • Limitations of Use
  • Metoclopramide is not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. (n n n , n n n )n nn
  • Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. (n n n )n n n
  • Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. (n n n )n n n
  • Gastroesophageal Reflux
  • Acute and Recurrent Diabetic Gastroparesis
  • Dosage Adjustment in Specific Populations
  • Oral Solution: 10 mg/10 mL metoclopramide
  • Oral Solution: 10 mg/10 mL metoclopramide (n n n )n nn
  • Metoclopramide is contraindicated:
  • History of TD or dystonic reaction to metoclopramide (n n n )n n n
  • When stimulation of gastrointestinal motility might be dangerous (n n n )n n n
  • Pheochromocytoma, catecholamine-releasing paragangliomas (n n n )n n n
  • Epilepsy (n n n )n n n
  • Hypersensitivity to metoclopramide (n n n )n n n
  • No data
  • Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS)
  • Depression and suicidal ideation/suicide
  • The following adverse reactions are described, or described in greater detail, in other sections of the labeling:
  • The following adverse reactions have been identified from clinical studies or postmarketing reports of metoclopramide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
  • The most common adverse reactions (in approximately 10% of patients receiving 10 mg of metoclopramide four times daily) were restlessness, drowsiness, fatigue, and lassitude. In general, the incidence of adverse reactions correlated with the dosage and duration of metoclopramide administration.
  • Adverse reactions, especially those involving the nervous system, occurred after stopping metoclopramide including dizziness, nervousness, and headaches.
  • Central Nervous System Disorders
  • Endocrine Disorders
  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Hepatic Disorders
  • Renal and Urinary Disorders
  • Hematologic Disorders
  • Hypersensitivity Reactions
  • Eye Disorders
  • Metabolism Disorders
  • To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • Most common adverse reactions (> 10%) are restlessness, drowsiness, fatigue, and lassitude. (n n n )n n n
  • No data
  • Antipsychotics
  • CNS depressants
  • Strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine)
  • MAO inhibitors
  • Additional drug interactions
  • No data
  • Manifestations of metoclopramide overdosage included drowsiness, disorientation, extrapyramidal reactions, other adverse reactions associated with metoclopramide use (including, e.g., methemoglobinemia), and sometimes death. Neuroleptic malignant syndrome (NMS) has been reported in association with metoclopramide overdose and concomitant treatment with another drug associated with NMS n n n n
  • There are no specific antidotes for metoclopramide overdosage. If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosagen n n n
  • Methemoglobinemia can be reversed by the intravenous administration of methylene blue. However, methylene blue may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which may be fatal.
  • Hemodialysis and continuous ambulatory peritoneal dialysis do not remove significant amounts of metoclopramide.
  • Metoclopramide, is a dopamine-2 receptor antagonist. Metoclopramide hydrochloride (metoclopramide monohydrochloride monohydrate) is a white crystalline, odorless substance, freely soluble in water. Its chemical name is 4-aminou00ad5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy benzamide monohydrochloride monohydrate.
  • The molecular formula is Cn n n Hn n n ClNn n n On n n u2219HClu2219Hn n n O. Its molecular weight is 354.3. The structural formula is:n nn
  • Metoclopramide Oral Solution USP is an orange-colored, berry-citrus flavored liquid for oral administration and is available in 10 mg/10 mL oral solution.
  • No data
  • No data
  • Metoclopramide Oral Solution USP, 5 mg metoclopramide base (as the monohydrochloride monohydrate) per 5 mL (teaspoonful) is available as an orange-colored, berry-citrus flavored, sugar-free solution and is supplied in the following oral dosage forms:
  • STORAGE
  • Dispense in a tight, light-resistant container. Store at controlled room temperature between 20u00b0C to 25u00b0C (68u00b0F to 77u00b0F).
  • Advise the patient to read the FDA-approved patient labeling (Medication Guide).
  • Inform patients or their caregivers that metoclopramide can cause serious adverse reactions. Instruct patients to discontinue metoclopramide and contact a healthcare provider immediately if the following serious reactions occur:
  • Inform patients or their caregivers that concomitant treatment with numerous other medications can precipitate or worsen serious adverse reactions such as tardive dyskinesia or other extrapyramidal reactions, neuroleptic malignant syndrome, and CNS depression n n n . Explain that the prescriber of any other medication must be made aware that the patient is taking metoclopramide.n nn
  • Inform patients or their caregivers that metoclopramide can cause drowsiness or dizziness, or otherwise impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle n n n .n nn
  • MANUFACTURED BYn n n n n
  • R09/17
  • No data
  • NDC 0121-0576-16
  • Metoclopramiden n n Oral Solution USPn n n
  • 5 mg/5 mL*
  • *Each 5 mL (1 teaspoonful) contains:n n n Metoclopramide 5 mgn n n (present as the hydrochloride)n nn
  • PHARMACIST: Dispense the accompanyingn n n Medication Guide to each patient.n n n
  • Rx ONLY
  • 16 fl oz (473 mL)
  • Arrayn- Pharmaceuticaln n n Associates, Inc.n n n
  • Delivers n n n n NDC 0121-1576-10n nn
  • Arrayn- 10 mg/10 mL
  • FOR INSTITUTIONAL USE ONLYn n n Rx ONLYn n n n- SEE INSERT
  • A15761001

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.